Depression is a highly prevalent and incident mental illness. Current pharmacological therapies fail in approximately 30-40% of patients, highlighting the urgent need for novel agents with pleiotropic effects. This preclinical study aimed to identify new antidepressants and cognitive modulators among five phytocannabinoids: cannabichromene, cannabidiol, cannabidivarin, cannabigerol and...
The discovery of the rapid antidepressant action of ketamine accelerated the identification of new molecules that are associated with fast and prolonged relief of depressive symptoms. As a result, a new group of antidepressants have emerged, some of them already approved for clinical use, classified as rapid-acting antidepressant drugs (RAADs). Potentiation of brain-derived neurotrophic factor...